Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

2 Babies Die, 29 Sickened from Bad Vaccines in South Mexico

By Drug Discovery Trends Editor | May 11, 2015

Mexico’s public health system has suspended infant vaccines and mounted an investigation after two babies died and 29 were sickened in an impoverished community in southern Mexico.

Six of the 29 babies are in grave condition after receiving vaccinations for tuberculosis, rotovirus and Hepatitis B, which are generally administered between 0 and 6 months, according to a national schedule. The cause of the adverse reactions is not known, the Mexican Institute for Social Security said Sunday.

The institute said it stopped vaccines nationwide on Saturday as a precaution.

The Rev. Marcelo Perez, a Roman Catholic priest, told The Associated Press that families of the babies said they became sick within hours. The adverse reactions started Friday and the babies were being treated in a hospital in Simojovel, Chiapas, where 93 percent of the people live in poverty, 69 percent in extreme poverty, according to government statistics.

The hospital “doesn’t have adequate personnel or equipment,” Perez said. “The real problem is the terrible conditions we have … so that when a baby comes in with convulsions, he leaves dead.”

The federal and state government, in a statement Sunday, promised the best medical care for the babies and to stay in contact with the parents to answer all their questions. Perez said he was helping the families collect all the information that could help officials discover the cause of the adverse reactions.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50